NeuroOne Medical Technologies Corporation — Form 8-K Summary
Report date: October 5, 2026. The company reported preliminary, unaudited results for the fiscal quarter and year ended September 30, 2026.
Financial and operating results
- Fiscal 2026 revenue: Approximately $10.5 million.
- Fiscal fourth-quarter revenue: Approximately $3.8 million.
- The filing provides no clear values for profit, cash flow, margins, debt, or liquidity.
Purchase order and outlook
- The company received a $4.5 million purchase order during September 2026. Approximately $1.0 million had shipped by September 30.
- Shipments of the remaining amount are expected to begin in fiscal Q1 2027 and continue into Q2, subject to manufacturing and delivery schedules. The filing describes the remaining amount as $3.6 million; this does not exactly reconcile with the approximate order and shipment figures.
- The filing gives no formal revenue guidance or other quantified outlook.
Comparisons and qualifications
No prior-period comparison is provided. Results are preliminary and unaudited, subject to management and audit committee review, closing procedures, and possible revision. The company cautions that actual results may differ materially.
Risks and investor verification
- Verify final audited fiscal 2026 results and any changes to the preliminary revenue figures.
- Confirm shipment timing and fulfillment of the purchase order, including the stated remaining balance.
- Consider the disclosed risks involving Nasdaq listing compliance, commercialization and product acceptance, supply and manufacturing, clinical and regulatory outcomes, reimbursement, intellectual property, and access to capital.